Accès gratuit
Numéro
Med Sci (Paris)
Volume 31, Numéro 2, Février 2015
Page(s) 180 - 186
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20153102015
Publié en ligne 4 mars 2015
  1. Brooks JD. Translational genomics: the challenge of developing cancer biomarkers. Genome Res 2012 ; 22 : 183–187. [CrossRef] [PubMed]
  2. Mandel P, Metais P. Les acides nucléiques du plasma sanguin chez l’homme. CR Séances Soc Biol Fil 1948 ; 142 : 241–243.
  3. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977 ; 37 : 646–650. [PubMed]
  4. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011 ; 11 : 426–437. [CrossRef] [PubMed]
  5. Gormally E, Caboux E, Vineis P, Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res 2007 ; 635 : 105–117. [CrossRef] [PubMed]
  6. Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001 ; 61 : 1659–1665. [PubMed]
  7. Van der Vaart M, Pretorius PJ. Is the role of circulating DNA as a biomarker of cancer being prematurely overrated? Clin Biochem 2010 ; 43 : 26–36. [CrossRef] [PubMed]
  8. Lo YMD, Zhang J, Leung TN, et al. Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet 1999 ; 64 : 218–224. [CrossRef] [PubMed]
  9. Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008 ; 14 : 985–990. [CrossRef] [PubMed]
  10. El Messaoudi S, Rolet F, Mouliere F, Thierry AR. Circulating cell free DNA: preanalytical considerations. Clin Chim Acta 2013 ; 424 : 222–230. [CrossRef] [PubMed]
  11. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 2013 ; 10 : 472–484. [CrossRef]
  12. Stroun M, Lyautey J, Lederrey C, et al. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta 2001 ; 313 : 139–142. [CrossRef] [PubMed]
  13. Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012 ; 486 : 532–536. [CrossRef] [PubMed]
  14. Lecomte T, Berger A, Zinzindohoue F, et al. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int J Cancer 2002 ; 100 : 542–548. [CrossRef] [PubMed]
  15. Robertson EG, Baxter G. Tumour seeding following percutaneous needle biopsy: the real story!. Clin Radiol 2011 ; 66 : 1007–1014. [CrossRef] [PubMed]
  16. Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the clinic. Nature 2013 ; 501 : 355–364. [CrossRef] [PubMed]
  17. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012 ; 366 : 883–892. [CrossRef] [PubMed]
  18. Diehl F, Li M, Dressman D, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA 2005 ; 102 : 16368–16373. [CrossRef]
  19. Thierry AR, Mouliere F, El Messaoudi S, et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med 2014 ; 20 : 430–435. [CrossRef] [PubMed]
  20. Taly V, Pekin D, Benhaim L, et al. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin Chem 2013 ; 59 : 1722–1731. [CrossRef] [PubMed]
  21. Taly V, Pekin D, El Abed A, Laurent-Puig P. Detecting biomarkers with microdroplet technology. Trends Mol Med 2012 ; 18 : 405–416. [CrossRef] [PubMed]
  22. Vogelstein B, Kinzler KW. Digital PCR. Proc Natl Acad Sci USA 1999 ; 96 : 9236–9241. [CrossRef]
  23. Thierry AR, Mouliere F, Gongora C, et al. Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. Nucleic Acids Res 2010 ; 38 : 6159–6175. [CrossRef] [PubMed]
  24. Didelot A, Kotsopoulos SK, Lupo A, et al. Multiplex picoliter-droplet digital PCR for quantitative assessment of DNA integrity in clinical samples. Clin Chem 2013 ; 59 : 815–823. [CrossRef] [PubMed]
  25. Oxnard GR, Paweletz CP, Kuang Y, et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 2014 ; 20 : 1698–1705. [CrossRef] [PubMed]
  26. Dawson SJ, Tsui DWY, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013 ; 368 : 1199–1209. [CrossRef] [PubMed]
  27. Gevensleben H, Garcia-Murillas I, Graeser MK, et al. Noninvasive detection of HER2 amplification with plasma DNA digital PCR. Clin Cancer Res 2013 ; 19 : 3276–3284. [CrossRef] [PubMed]
  28. Hindson BJ, Ness KD, Masquelier DA, et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem 2011 ; 83 : 8604–8610. [CrossRef] [PubMed]
  29. Pekin D, Skhiri Y, Baret JC, et al. Quantitative and sensitive detection of rare mutations using droplet-based microfluidics. Lab Chip 2011 ; 11 : 2156–2166. [CrossRef] [PubMed]
  30. Diaz LA Jr,Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012 ; 486 : 537–540. [PubMed]
  31. Yung TKF, Chan KCA, Mok TSK, et al. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res 2009 ; 15 : 2076–2084. [CrossRef] [PubMed]
  32. Kimura H, Kasahara K, Shibata K, et al. EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer. J Thorac Oncol 2006 ; 1 : 260–267.
  33. Taniguchi K, Uchida J, Nishino K, et al. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res 2011 ; 17 : 7808–7815. [CrossRef] [PubMed]
  34. Page K, Hava N, Ward B, et al. Detection of HER2 amplification in circulating free DNA in patients with breast cancer. Br J Cancer 2011 ; 104 : 1342–1348. [CrossRef] [PubMed]
  35. Moltzahn F, Olshen AB, Baehner L, et al. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res 2011 ; 71 : 550–560. [CrossRef] [PubMed]
  36. Ma J, Li N, Guarnera M, Jiang F. Quantification of plasma miRNAs by digital PCR for cancer diagnosis. Biomark Insights 2013 ; 8 : 127–136. [PubMed]
  37. Li M, Chen WD, Papadopoulos N, et al. Sensitive digital quantification of DNA methylation in clinical samples. Nat Biotechnol 2009 ; 27 : 858–863. [CrossRef] [PubMed]
  38. Riethdorf S, Fritsche H, Muller V, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the cell search system. Clin Cancer Res 2007 ; 13 : 920–928. [CrossRef] [PubMed]
  39. Pfitzner C, Schröder I, Scheungraber C, et al. Digital-direct-RT-PCR: a sensitive and specific method for quantification of CTC in patients with cervical carcinoma. Sci Rep 2014 ; 4 : 3970. [CrossRef] [PubMed]
  40. Sedlak RH, Jerome KR. Viral diagnostics in the era of digital polymerase chain reaction. Diagn Microbiol Infect Dis 2012 ; 75 : 1–4. [CrossRef] [PubMed]
  41. Lo YM, Chiu RW. Noninvasive prenatal diagnosis of fetal chromosomal aneuploidies by maternal plasma nucleic acid analysis. Clin Chem 2008 ; 54 : 461–466. [CrossRef] [PubMed]
  42. Baker M.. Digital PCR hits its stride. Nat Meth 2012 ; 9 : 541–544. [CrossRef]
  43. Perez-Toralla K, Pekin D, Bartolo JF, et al. PCR digitale en microcompartiments : détection sensible de séquences d’acides nucléiques rares. Med sci (Paris) 2015 : 84–92. [CrossRef] [EDP Sciences] [PubMed]
  44. Bournet B, Dufresne M, Selves J, et al. Oncogène Kras et cancer du pancréas. Med Sci (Paris) 2013 ; 29 : 991–997. [CrossRef] [EDP Sciences] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.